A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RESPOND
- Sponsors Biogen
- 20 Nov 2018 Primary endpoint has been met. (Annualized Relapse Rate) as per results published in the Clinical Therapeutics.
- 20 Nov 2018 Results published in the Clinical Therapeutics
- 28 Apr 2017 Results of an post hoc subgroup analysis presented at the 69th Annual Meeting of the American Academy of Neurology